The pace of innovation in biotech: Mirador’s Mark McKenna

Market Context & Ecosystem Shifts

• The biotech ecosystem has evolved from a handful of large-cap pharma giants (e.g., Merck, J&J) dominating for 100+ years to a modern landscape of ~700 public biotech companies.
• Approximately 80% of these public biotechs are currently focused on oncology, while the remaining 20% target other indications like autoimmune diseases.
• Big Pharma is characterized by strengths in capital allocation, process development, and commercialization, but is often perceived as too slow and risk-averse.
• Biotech firms fill the innovation gap by operating with higher risk tolerance, speed, and agility, pioneering paths that large incumbents cannot.

Leadership & Organizational Lessons

• Success in biotech requires translating "cowboy" scientific brilliance into collaborative organizational output, emphasizing people leadership over pure technical prowess.
• Effective leadership involves managing conflict and fostering transparent cultures where boards and advisors provide honest feedback rather than acting as "yes people."
• Founders must be prepared to pivot strategies mid-flight, such as restructuring a mixed business model (diagnostics vs. therapeutics) to focus on the value-driving therapeutic side.

Entrepreneurial Journey & Deal History

• Mark McKenna previously led Prometheus Biosciences, which was sold to Merck for $11 billion; he now leads Mirador Therapeutics, a precision medicine company focused on autoimmune and inflammatory diseases.
• At Prometheus, the company raised $1 billion privately and publicly to reach Phase 2 before the sale; the sale funded ~110 of 120 employees to become millionaires.
• In a previous venture, the company faced a capital gap upon arrival; McKenna secured $20 million in a European partnership and subsequently raised $130 million within 12 months to fund the lead drug through mid-Phase 2.
• The Prometheus Phase 2 data exceeded expectations, showing remission rates of 25% (vs. 10-15% guidance) and a biomarker stratification of 35%, triggering intense M&A interest from 17 groups.
• Despite strong interest, the board rejected partnership offers in favor of an acquisition, ultimately selling the company to Merck to avoid extending the path to market by four years.

Strategic Fundraising & Network Value

• Intentional network building transformed the fundraising environment: a previous raise took 12 months to secure $130 million, whereas Mirador Therapeutics raised $400 million in just two days upon launch.
• Transparency regarding risks and data was a key differentiator in building investor trust prior to the $11 billion exit.
• Mirador's current $400 million raise is structured to be "bet on the team" with only broad areas disclosed (precision immunology), keeping specific assets under stealth to prevent Chinese competitors from mimicking the technology.

Drug Pricing, Supply Chain & Policy

• McKenna identifies Pharmacy Benefit Managers (PBMs) as a primary barrier to lower drug costs, noting that ~50% of a $50,000 drug price may return to insurers and PBMs rather than funding R&D.
• He advocates for shifting away from high-deductible plans toward "first-dollar" coverage to prevent shifting financial burdens onto employees.
• A significant risk identified is the over-reliance on China for drug manufacturing and substance development, necessitating a de-risking strategy through domestic (US) and European manufacturing capabilities.
• Intellectual property in antibody drugs is vulnerable to "fast follower" strategies where minor sequence tweaks allow competitors to bypass patents and enter the market rapidly.

Operational Philosophy: Speed vs. Safety

• "Speed is the new currency" in biotech; running experiments in parallel is often cheaper than sequential processes when accounting for high monthly burn rates ($3-4 million).
• Running in parallel does not imply cutting safety corners, but rather optimizing the hypothesis testing cycle to accelerate patient access to treatments.
• Approximately 75% of current market drugs originated in small companies before being acquired by larger entities for Phase 3 trials and commercialization.
• Big Pharma's rigor often extends timelines by several years, delaying patient access to effective therapies.

Role of AI & Data in Precision Medicine

• Generative AI and machine learning are predicted to have the greatest impact on healthcare innovation in the last 100 years, surpassing previous technological shifts.
• AI enables the synthesis of massive datasets (e.g., 20,000 paired patient blood/tissue samples with clinical metadata) to identify genetic phenotypes and responder/non-responder patterns.
• Mirador utilizes internal LLMs trained on published literature to assist scientists in synthesizing information on complex disease variants, reducing reliance on individual memory.
• Data stratification allows for more precise patient selection, directly improving efficacy rates and moving the field toward curing conditions like cancer and autoimmune diseases.